TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02800486: Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Sponsor: Northwell Health · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 37 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT02800486 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02800486 Rescue Dossier →